OPTALGIN TABLETS Izrael - angol - Ministry of Health

optalgin tablets

teva pharmaceutical industries ltd, israel - dipyrone - tablets - dipyrone 500 mg - metamizole sodium - metamizole sodium - relief of moderate to severe pain as in headache, toothache, dysmenorrhea andfor high fever that does not respond to other measures.

OPTALGIN TABLETS Izrael - angol - Ministry of Health

optalgin tablets

teva israel ltd - dipyrone - tablets - dipyrone 500 mg - metamizole sodium - relief of moderate to severe pain as in headache, toothache, dysmenorrhea andfor high fever that does not respond to other measures.

ARCOXIA 60 MG TABLETS Izrael - angol - Ministry of Health

arcoxia 60 mg tablets

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 60 mg - etoricoxib - etoricoxib - arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra) and ankylosing spondylitis.

ARCOXIA 90 MG TABLETS Izrael - angol - Ministry of Health

arcoxia 90 mg tablets

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 90 mg - etoricoxib - etoricoxib - arcoxia 90 mg tablets are indicated for the symptomatic relief of rheumatoid arthritis (ra) and ankylosing spondylitis.for the short-term treatment of moderate pain associated with dental surgery.

ARCOXIA 120 MG TABLETS Izrael - angol - Ministry of Health

arcoxia 120 mg tablets

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 120 mg - etoricoxib - etoricoxib - arcoxia 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.

OLMEKAR HCT 40/5/25 Olmesartan medoxomil, Amlodipine (as besilate) and Hydrochlorothiazide 40 mg/5 mg/25 mg tablets blister pack Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

olmekar hct 40/5/25 olmesartan medoxomil, amlodipine (as besilate) and hydrochlorothiazide 40 mg/5 mg/25 mg tablets blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - it is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination.this fixed dose combination is not indicated for initial therapy.

NOXAFIL 100 MG GASTRO-RESISTANT TABLETS Izrael - angol - Ministry of Health

noxafil 100 mg gastro-resistant tablets

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - gastro resistant tablets - posaconazole 100 mg - posaconazole - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults:- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

HEXAKAPRON  TABLETS Izrael - angol - Ministry of Health

hexakapron tablets

teva israel ltd - tranexamic acid - tablets - tranexamic acid 500 mg - tranexamic acid - tranexamic acid - treatment of hemorrhage occuring in some forms of surgery, including prostatectomy. hematuria. menorrhagia. hereditary angioneurotic edema.

BETNESOL TABLETS Izrael - angol - Ministry of Health

betnesol tablets

devries & co. ltd - betamethasone - tablets - betamethasone 0.5 mg - betamethasone - betamethasone - diseases responsive to oral glucocorticosteroid therapy.

TAVANIC TABLETS 500 MG Izrael - angol - Ministry of Health

tavanic tablets 500 mg

sanofi israel ltd - levofloxacin as hemihydrate - film coated tablets - levofloxacin as hemihydrate 500 mg - levofloxacin - levofloxacin - tavanic tablets 500 mg is indicated in adults for the treatment of the following infections:- acute pyelonephritis and complicated urinary tract infections - chronic bacterial prostatitisin the below-mentioned infections, tavanic should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.- acute bacterial sinusitis - acute exacerbations of chronic obstructive pulmonary disease including bronchitis - community-acquired pneumonia- complicated skin and soft tissue infections.tavanic may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.consideration should be given to official guidance on the appropriate use of antibacterial agents.